<DOC>
	<DOCNO>NCT00427427</DOCNO>
	<brief_summary>The purpose study determine factor affect patient 's decision accept delayed Herceptin® treatment complete surgery and/or chemotherapy and/or radiation therapy . Women invasive breast cancer HER-2 positive ( FISH + ) determination 2004 thereafter complete surgery primary treatment earlier potentially eligible . Patients ask complete questionnaire breast cancer reason may may accept Herceptin® treatment . Patients give option ( 1 ) receive Herceptin® 52 week annual doctor visit 5 year ( 2 ) receive Herceptin® agree annual doctor visit 5 year .</brief_summary>
	<brief_title>Delayed Adjuvant Herceptin® Treatment Patients With HER-2 Positive Breast Cancer</brief_title>
	<detailed_description>Study Phase- Phase II Study Type- Interventional Study Design- This open label , non-randomized phase II study patient non-metastatic HER-2 positive breast cancer FISH diagnose 2004 thereafter . Potential patient sign write ICF prior complete questionnaire design determine factor may affect patient 's acceptance Herceptin® treatment . After answer questionnaire , patient give follow option : 1. receive one year trastuzumab treatment annual follow-up 5 year 2. decline trastuzumab treatment serve comparison group member monitoring safety effectiveness trastuzumab annual follow-up 5 year</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Confirmed nonmetastatic infiltrating carcinoma breast . 2 . HER2 amplify ( FISH + ) determination 2004 thereafter . 3 . ECOG performance status 02 . 4 . Patients 18 year age old . 5 . HER2 status determine FISH test . 6 . The following criterion applicable trastuzumab treatment group : Normal LVEF determine ECHO MUGA . If baseline LVEF &gt; 75 % , LVEF shall repeat determine falsely elevate . Adequate bone marrow function indicate follow : ANC &gt; 1500/mL , Platelets &gt; /=100,000/mL , Hemoglobin &gt; 9 g/dL Adequate renal function , indicate serum creatinine &lt; /= 1.5 x ULN Adequate liver function , indicate total bilirubin &lt; /= 1.5 x ULN AST ALT &lt; 2 x ULN unless related primary disease . If female childbearing potential , pregnancy test ( blood urine ) negative agrees use effective birth control method duration study . 7 . Signed informed consent obtain . 1 . Nonconfirmed HER2 positive FISH infiltrating carcinoma breast . 2 . Evidence metastatic disease . 3 . Previous trastuzumab treatment . 4 . Concurrent anticancer treatment hormonal agent ( tamoxifen , aromatase inhibitor ) radiotherapy . 5 . Patient history active cardiac disease , include cardiomyopathy , congestive heart failure , prior myocardial infarction , arrhythmia . 6 . Symptomatic intrinsic lung disease result dyspnea rest . 7 . Concurrent lifelimiting disease life expectancy le one year . 8 . Pregnancy , nurse woman , fertile woman practice birth control . 9 . Inability give inform consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>non-metastatic breast cancer</keyword>
	<keyword>HER-2 positive breast cancer</keyword>
	<keyword>Herceptin ( trastuzumab )</keyword>
	<keyword>delay adjuvant therapy</keyword>
	<keyword>acceptability rate</keyword>
	<keyword>non-metastatic , HER-2 positive breast cancer</keyword>
</DOC>